Skip to Content

New Drug Approvals Archive - November 2012

November 2012

Xeljanz (tofacitinib) Tablets

Date of Approval: November 6, 2012
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis

Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis.

Flucelvax (influenza virus vaccine)

Date of Approval: November 20, 2012
Company: Novartis
Treatment for: Influenza Prophylaxis

Flucelvax (influenza virus vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza.

Cometriq (cabozantinib) Capsules

Date of Approval: November 29, 2012
Company: Exelixis, Inc.
Treatment for: Thyroid Cancer

Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.